| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000010227 |
| Receipt No. | R000011974 |
| Official scientific title of the study | Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin for HER2-positive operable breast cancer: KBOG-1204 trial |
| Date of disclosure of the study information | 2013/03/12 |
| Last modified on | 2018/08/03 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin for HER2-positive operable breast cancer: KBOG-1204 trial | |
| Title of the study (Brief title) | Neoadjuvant TCbH therapy for HER2-positive breast cancer: KBOG-1204 trial | |
| Region |
|
|
| Condition | ||
| Condition | breast cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Efficacy (histopathological response) |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Pathological complete response rate |
| Key secondary outcomes | Cardiac adverse events, Breast-conserving rate, Clinical response rate, Relapse-free survival, Overall survival |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Neoaduvant chemotherapy with Docetaxel+Carboplatin+Trastuzumab
|
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1) invasive breast cancer by needle biopsy
2) operable primary breast cancer 3) HER2 positive (IHC 3+ or FISH +) 4) ER, PgR known 5) P.S. = 0~1 6) measurable lesions 7) preserving the functions of bone marrow, heart, liver, and kidney 8) written informed consent |
|||
| Key exclusion criteria | 1) drug allergy
2) severe complications (malignant hypertension, congestive heart failure, coronary heart disease, myocardial infarction (onset within 6 months), arrhythmia (treated), infectious disease, bleeding tendency, etc) 3) feber, infection 4) peripheral neuropathy 5) pleural effusion, pericardial effusion 6) active double cancer 7) inflammatory breast cancer 8) bilateral breast cancer, male breast cancer 9) pregnancy 10) severe edema 11) interstitial pneumonia, fibrous lung disease 12) steroid-using patients 13) psychosomatic disease 14) unsuitable patients |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Koichiro Tsugawa, M.D. |
| Organization | St. Marianna University School of Medicine |
| Division name | Department of Surgery, Division of Breast and Endocrine Surgery |
| Address | 2-16-1, Sugao, Miyamae-ku, Kawasaki-city, Kanagawa, Japan |
| TEL | 044-977-8111 |
| koitsuga@marianna-u.ac.jp | |
| Public contact | |
| Name of contact person | Yasuyuki Kojima, M.D. |
| Organization | St. Marianna University School of Medicine |
| Division name | Department of Surgery, Division of Breast and Endocrine Surgery |
| Address | 2-16-1, Sugao, Miyamae-ku, Kawasaki-city, Kanagawa, Japan |
| TEL | 044-977-8111 |
| Homepage URL | |
| kojiyasu@marianna-u.ac.jp | |
| Sponsor | |
| Institute | Kanagawa Breast Oncology Group (KBOG) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kanagawa Breast Oncology Group (KBOG) |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東海大学付属病院、聖マリアンナ医科大学病院、聖マリアンナ医科大学附属ブレスト&イメージングセンター、横浜市立大学附属市民総合医療センター、北里大学病院、神奈川県立がんセンター、大船中央病院、横浜労災病院、湘南記念病院、みなと赤十字病院、横浜旭中央総合病院、東海大学付属八王子病院、横浜市立大学附属病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011974 |